Reviva Q3 net loss $3.5M; cash $23.2M; Phase 3 enrollment >30%, topline mid-2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss of $3.5M ($0.18 per share) for Q3 2022 vs $2.3M ($0.12) in Q3 2021.
Cash $23.2M as of Sep 30, 2022, down from $29.7M at Dec 31, 2021; sufficient through Nov 2023.
Phase 3 RECOVER trial for brilaroxazine enrolled >30% in US; topline data expected mid-2023.
Announced $8.5M registered direct offering in September 2022.
Exploring non-dilutive financing for expansion into bipolar, MDD, ADHD, PAH, IPF indications.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the nine months ended September 30, 2022 results: net income approximately $16.2 million, EPS ($0.87) per share.

Period: the nine months ended September 30, 2022
Net income: approximately $16.2 million
EPS: ($0.87) per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $16.2 million, or ($0.87) per share, for the nine months ended September 30, 2022, compared to a net loss of approximately $4.8 million, or ($0.36) per share, for the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the three months ended September 30, 2022 results: net income approximately $3.5 million, EPS ($0.18) per share.

Period: the three months ended September 30, 2022
Net income: approximately $3.5 million
EPS: ($0.18) per share
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $3.5 million, or ($0.18) per share, for the three months ended September 30, 2022, compared to a net loss of approximately $2.3 million, or ($0.12) per share, for the same period in 2021.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-027263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.